It has been reported that serum IL-6 levels in NSCLC patients (especially metastatic cases) are higher than healthy subjects77,78, and blockade of IL-6/STAT3 signalling results in the inhibition of lung tumour growth109. This evidence concerns the gene STAT3 and lung neoplasm.